BT-001

AXP000095.1 · Oncolytic virus

Platform
vaccinia virus (Copenhagen, TK- RR-)
Originator
Transgene; BioInvent International
Sponsor
Transgene

Names

NameTypeSource
BT-001preferred name, codecurator, ncit
TG6030codectgov

Virus

Role
Oncolytic
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
Copenhagen
Replication
conditionally replicating
Modifications
J2R (thymidine kinase) and I4L (ribonucleotide reductase) deleted
Transgenes
anti-CTLA-4 antibody (4-E03), CSF2
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C179623

Approvals

No regulatory approval recorded.

Clinical trials (6)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07687875Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal CancerRecruitingPhase 12026-10-232028-12-3120Rectal Cancer Patients
NCT05302050A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes MellitusUnknown2022-03-072025-12-01500Diabetes Type 2
NCT05266625Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical TherapyUnknown2022-02-142025-11500Diabetes Mellitus, Type 2
NCT05094401Use of an Investigational Digital Therapeutic in Patients With Type 2 DiabetesTerminatedPhase 32021-10-042023-04-0176Type2 Diabetes
NCT04886388Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 DiabetesCompletedPhase 32021-04-222022-03-09668Type 2 Diabetes
NCT04725331A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsTerminatedPhase 1/22021-02-252025-10-2231Melanoma; Merkel Cell Carcinoma; Metastatic Cancer; Non Small Cell Lung Cancer; Soft Tissue Sarcoma; Triple Negative Breast Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 38170435Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes.Advances in therapy2024name in abstract: BT-001
PMID 35778834Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, controlled trial.Clinical cardiology2022name in abstract: BT-001
PMID 36181554Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes.Diabetes care2022name in abstract: BT-001

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42979039Digital Cognitive Behavioral Therapy Reduces Intensification of Antihyperglycemic Therapy in Patients With Type 2 Diabetes.AACE endocrinology and diabetes2026name in abstract: BT-001
PMID 36592462In type 2 diabetes, the BT-001 smartphone app reduced HbA1c more than a control app at 90 d.Annals of internal medicine2023name in title: BT-001
PMID 35058324Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.Journal for immunotherapy of cancer2022name in abstract: BT-001

Notes

Also coded TG6030. Armed with the BioInvent anti-CTLA-4 antibody 4-E03 and GM-CSF; phase I/IIa NCT04725331 terminated 2025.

How to cite

BT-001 (AXP000095.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000095.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.